STOCK TITAN
  1. Home
  2. Sec-filings
  3. ODYY
  4. [8-K] Odyssey Health, Inc. Reports Material Event

Odyssey Health says NeuRX cancels BreastCheck agreement

Odyssey Health, Inc. reports that NeuRX Health, Inc. sent a formal letter on May 6, 2026 stating that the definitive agreement between NeuRX and Odyssey dated October 14, 2025, which closed on April 21, 2026, is immediately cancelled.

Filing Impact
(Moderate)
Filing Sentiment
(Neutral)
Form Type
8-K

Rhea-AI Filing Summary

Odyssey Health, Inc. reports that NeuRX Health, Inc. sent a formal letter on May 6, 2026 stating that the definitive agreement between NeuRX and Odyssey dated October 14, 2025, which closed on April 21, 2026, is immediately cancelled.

The letter relates to NeuRX’s sublicensing of Davion Healthcare Plc’s BreastCheck product to Odyssey and refers to issues with required consents and approvals under Davion’s arrangements. Odyssey has filed the NeuRX revocation letter as an exhibit to this report.

Positive

  • None.

Negative

  • NeuRX agreement cancellation: NeuRX’s May 6, 2026 letter states that the definitive agreement with Odyssey, tied to the BreastCheck product sublicensing, is immediately cancelled, potentially affecting Odyssey’s planned product or partnership strategy.

Insights

Cancellation of the NeuRX agreement removes access to a planned BreastCheck product relationship for Odyssey.

The report describes NeuRX’s notice that its definitive agreement with Odyssey Health concerning a sublicensing arrangement for Davion’s BreastCheck product is immediately cancelled. This agreement was signed in October 2025 and closed in April 2026, so it was a recently completed transaction.

Loss of such an agreement can affect a company’s product pipeline or partnership strategy, depending on how central BreastCheck was expected to be. The filing also references a related report and includes the NeuRX revocation letter as an exhibit, indicating that further detail may appear in associated disclosures.

Item 1.01 Entry into a Material Definitive Agreement Business
The company signed a significant contract such as a merger agreement, credit facility, or major partnership.
Item 9.01 Financial Statements and Exhibits Exhibits
Financial statements, pro forma financial information, or exhibit attachments filed with this report.
NeuRX revocation letter date May 6, 2026 Date of NeuRX formal written notice cancelling the agreement
Definitive agreement date October 14, 2025 Date the Odyssey–NeuRX definitive agreement was signed
Agreement closing date April 21, 2026 Closing date of the Odyssey–NeuRX definitive agreement
Exhibit 10.1 NeuRX Revocation Letter Revocation letter dated May 6, 2026 filed as exhibit
Exhibit 104 Cover Page Inline XBRL Cover page interactive data file embedded in Inline XBRL
definitive agreement financial
"the definitive agreement between Odyssey and NeuRX, dated October 14, 2025, and which closed on April 21, 2026"
A definitive agreement is a formal, legally binding document that outlines the final terms and conditions of a deal or transaction, such as a sale or partnership. It acts like a detailed contract that confirms all parties have agreed on the key details, making the deal official. For investors, it signals that the agreement is settled and moving toward completion, providing clarity and security about the transaction.
Representations and Warranties financial
"NeuRX breached the Representations and Warranties contained in the definitive agreement"
Representations and warranties are statements one party makes to another in a legal agreement about facts or conditions that are true at signing or will be true in the future, like ownership, financial statements, or regulatory compliance. They matter to investors because they set the factual baseline for a deal—like guarantees in a car sale—and create legal remedies or payment adjustments if those statements turn out to be false, affecting value and risk.
sublicensing financial
"prior to sublicensing the BreastCheck product to Odyssey"
emerging growth company regulatory
"Emerging growth company"
An emerging growth company is a recently public or smaller public firm that qualifies for temporary, lighter regulatory and disclosure rules to reduce the cost and effort of being public. For investors, it means the company may provide less historical financial detail and face fewer reporting requirements than larger firms, so it can grow more quickly but also carries higher uncertainty—like buying a promising early-stage product with fewer user reviews.
Inline XBRL technical
"Cover Page Interactive Data File (embedded within the Inline XBRL document)"
Inline XBRL is a file format for financial filings that embeds machine-readable data tags directly inside the human-readable report, so the same document can be read by people and parsed by software. For investors it makes extracting, comparing and verifying financial numbers faster and more reliable—like a grocery list where each item also has a barcode—reducing manual errors and speeding up analysis.

FAQ

What event did Odyssey Health (ODYY) report on May 6, 2026?
Odyssey Health reported receiving a formal letter dated May 6, 2026 from NeuRX Health stating that the definitive agreement between the parties is immediately cancelled. The agreement involved a sublicensing arrangement connected to Davion Healthcare’s BreastCheck product.

Which agreement between Odyssey Health (ODYY) and NeuRX was cancelled?
The cancelled agreement is the definitive agreement between Odyssey Health and NeuRX Health dated October 14, 2025, which had closed on April 21, 2026. NeuRX’s May 6, 2026 letter states that this agreement is immediately cancelled.

How is Davion’s BreastCheck product involved with Odyssey Health (ODYY)?
Davion Healthcare’s BreastCheck product is involved through a sublicensing chain. NeuRX Health had sublicensed the BreastCheck product to Odyssey under the definitive agreement. The reported cancellation concerns that sublicensing arrangement and related consents and approvals under Davion’s contractual framework.

When did the Odyssey–NeuRX definitive agreement originally close?
The definitive agreement between Odyssey Health and NeuRX Health, dated October 14, 2025, closed on April 21, 2026. NeuRX’s subsequent letter dated May 6, 2026 states that this agreement is immediately cancelled, despite its recent closing date.

What type of SEC filing did Odyssey Health (ODYY) use for this disclosure?
Odyssey Health used a current report on Form 8-K to disclose the NeuRX letter cancelling the definitive agreement. Form 8-K is typically used to report significant events or changes that shareholders and the market may consider important.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
false 0001626644 0001626644 2026-05-06 2026-05-06 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

FORM 8-K

 

Current Report

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

 

Date of Report: May 6, 2026

(Date of earliest event reported)

 

ODYSSEY HEALTH, INC.

(Exact name of registrant as specified in its charter)

 

 

Nevada 000-56196 47-1022125
(State or other jurisdiction of incorporation) (Commission File Number) (IRS Employer Identification Number)

 

2300 West Sahara Avenue, Suite 800 - #4012,
Las Vegas, NV		 89102
(Address of principal executive offices) (Zip Code)

 

(702) 780-6559

(Registrant’s telephone number, including area code)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class Trading Symbol(s) Name of each exchange on which registered
N/A N/A N/A

 

Securities registered pursuant to Section 12(g) of the Act:

 

Title of each Class Trading Symbol Name of Each Exchange on Which Registered
Common Stock ($0.001 par value) ODYY OTC

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b2 of the Securities Exchange Act of 1934 (§240.12b2 of this chapter). Emerging growth company ☐

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

   

 

 

Item 1.01. Entry into a Material Definitive Agreement.

 

On May 6, 2026, Odyssey Health, Inc., a Nevada corporation (the "Company" "Odyssey"), received formal written notice from NeuRX Health, Inc. ("NeuRX"), a Wyoming corporation, advising that NeuRX is in breach of its contractual obligations with Davion Healthcare Plc ("Davion"), an Irish corporation, in connection with Davion's BreastCheck product. Specifically, NeuRX failed to obtain Davion's required approval prior to sublicensing the BreastCheck product to Odyssey. In addition, NeuRX breached the Representations and Warranties contained in the definitive agreement, under which NeuRX had expressly warranted to Odyssey that all necessary consents and approvals had been obtained. As a result, the notice stated that the definitive agreement between Odyssey and NeuRX, dated October 14, 2025, and which closed on April 21, 2026, is immediately cancelled.

 

The information set forth in this Form 8-K Current Report filed on May 11, 2026, is hereby incorporated by reference into this Form 8-K Current Report. 

 

Item 9.01. Financial Statements and Exhibits.

 

(d) Exhibits.

 

Exhibit No. Description
10.1

NeuRX Health, Inc. Revocation Letter dated May 6, 2026.

104 Cover Page Interactive Data File (embedded within the Inline XBRL document)

 

 

 

 

 

 

 

 

 2 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

Odyssey Health, Inc.

   
Date: May 11, 2026 By:  /s/ Joseph Michael Redmond
    Joseph Michael Redmond
Chief Executive Officer

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 3 

Source: View Original Filing on SEC EDGAR

Filing Exhibits & Attachments

4 documents

Agreements & Contracts

Other Documents

Keep reading

More on ODYY

Trending in the feed

Open the live feed